Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$38.29 USD

38.29
466,495

+0.83 (2.22%)

Updated Jul 9, 2024 04:00 PM ET

After-Market: $38.25 -0.04 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IMCR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Immunocore Holdings PLC Sponsored ADR [IMCR]

Reports for Purchase

Showing records 1 - 20 ( 32 total )

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 1

06/05/2024

Company Report

Pages: 11

ASCO Takeaways: PRAME Bispecific Achieves Durable Disease Control in Cutaneous Melanoma

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 2

05/30/2024

Company Report

Pages: 7

TEBE-AM Converts to Phase 3, Placing Data Readout on Track for 2026 in Cutaneous Melanoma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 3

05/24/2024

Daily Note

Pages: 3

ASCO Takeaways: Promising Clinical Activity With Lead PRAME Bispecific Program in Cutaneous Melanoma; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 4

05/09/2024

Company Report

Pages: 10

KIMMTRAK Does Not Miss a Beat; PRAME Franchise Poised to Shine at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 5

04/22/2024

Industry Report

Pages: 5

Key Takeaway From Biotech Breakthroughs Oncology Event: The Rise of PRAME-Targeted Therapies

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 6

03/06/2024

Company Report

Pages: 6

Pipeline and Commercialization Efforts Firing on All Cylinders; 4Q23 Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 7

02/14/2024

Industry Report

Pages: 70

Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 150.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 8

01/17/2024

Company Report

Pages: 7

Differentiated Bispecific Biologics Pipeline on Track in Oncology, Infectious Disease, and Autoimmunity; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 9

01/05/2024

Daily Note

Pages: 3

Multiple PRAME Readouts Expected in 2024; Pipeline Expansion on Track Including to Autoimmunity; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 10

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for IMCR 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 11

11/09/2023

Company Report

Pages: 9

3Q23 Results; KIMMTRAK Launch Impresses; Pipeline Advances

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 12

10/30/2023

Company Report

Pages: 7

HBV Conference Takeaways: Lead Program Advancing Through Phase 1 With Next Updates on Track for 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 13

10/24/2023

Company Report

Pages: 12

ESMO Data Support Long-Term Survival Benefit of KIMMTRAK in Uveal Melanoma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 14

09/19/2023

Industry Report

Pages: 14

Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 15

08/23/2023

Company Report

Pages: 8

KIMMTRAK Launch Progressing; PRAME Program Expanding; Momentum Building Ahead of Next Catalysts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 16

08/11/2023

Company Report

Pages: 12

2Q23 Results; PRAME Advances to Phase 3 in Cutaneous Melanoma; KIMMTRAK Launch and Pipeline on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 17

05/12/2023

Company Report

Pages: 9

1Q23 Results; Robust KIMMTRAK Launch

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 18

05/09/2023

Company Report

Pages: 8

Management Meeting Highlights Year of Execution in 2023 Ahead of Many Expected Catalysts in 2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 19

04/19/2023

Company Report

Pages: 14

AACR Data Details KIMMTRAK''s Differentiation in Uveal Melanoma; Compelling Preclinical Data Emerges; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Immunocore Holdings PLC Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 20

03/08/2023

Company Report

Pages: 10

Maintains Momentum on KIMMTRAK; Expands PRAME; Impresses With Initial HIV Data; Exits MAGE; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party